TriSalus Life Sciences (NASDAQ:TLSI) Raised to Hold at Wall Street Zen

TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other equities analysts have also issued reports on TLSI. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Monday, December 29th. Zacks Research upgraded shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 16th. Finally, Canaccord Genuity Group reduced their target price on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating for the company in a report on Friday. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, TriSalus Life Sciences currently has a consensus rating of “Hold” and a consensus target price of $7.00.

TriSalus Life Sciences Stock Down 6.3%

Shares of TriSalus Life Sciences stock opened at $4.47 on Friday. The company has a 50 day moving average price of $5.36 and a 200 day moving average price of $5.36. The firm has a market capitalization of $223.77 million, a P/E ratio of -2.44 and a beta of 0.42. TriSalus Life Sciences has a 52 week low of $3.42 and a 52 week high of $7.95.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.01. The firm had revenue of $13.21 million during the quarter, compared to analysts’ expectations of $13.20 million. As a group, research analysts anticipate that TriSalus Life Sciences will post -1.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Police & Firemen s Retirement System of New Jersey purchased a new stake in TriSalus Life Sciences in the 2nd quarter worth approximately $29,000. JPMorgan Chase & Co. increased its holdings in shares of TriSalus Life Sciences by 35,804.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after purchasing an additional 7,519 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of TriSalus Life Sciences in the 2nd quarter valued at $47,000. Invesco Ltd. purchased a new stake in TriSalus Life Sciences during the fourth quarter worth $72,000. Finally, Abel Hall LLC acquired a new stake in TriSalus Life Sciences during the fourth quarter valued at $73,000. 2.58% of the stock is owned by institutional investors and hedge funds.

TriSalus Life Sciences News Summary

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: Q4 results slightly beat expectations — TLSI reported ($0.12) EPS vs. a ($0.13) consensus and revenue of $13.21M vs. $13.20M expected, a small but constructive beat that supports near‑term operational momentum. Earnings Call Highlights
• Positive Sentiment: Company reaffirmed FY2026 revenue guidance of $60M–$62M and said it is expanding its PEDD portfolio — guidance above Street revenue consensus may support longer‑term growth expectations. Guidance & PEDD Expansion
• Positive Sentiment: Brokerage support remains: Lake Street reaffirmed its buy stance, keeping institutional endorsement visible to investors. Lake Street Rating
• Neutral Sentiment: Full earnings call transcripts and coverage are available (useful for detail but not new headline items) — investors can review management commentary on growth initiatives and margins. Earnings Call Transcript
• Neutral Sentiment: Independent estimates and models updated by firms such as Northland provide refreshed forecasts but contain no single consensus surprise; these are reference points for investors modeling FY2026. Northland Estimates
• Negative Sentiment: Canaccord cut its price target from $12 to $7 while keeping a buy rating — the sizable downgrade in upside reduces some analyst‑driven upside expectations and likely pressured the stock despite the buy rating. Canaccord Price Target Cut

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.